healthneutral
A New Hope for Depression Sufferers
Monday, February 10, 2025
The study found that those who used esketamine NS had 43. 2% more weeks with functional remission compared to those who used quetiapine XR. This difference was statistically significant, meaning it was likely not due to chance.
When it came to work productivity, esketamine NS users had a 14. 2% reduction in overall work productivity loss. This was a big deal because it showed that esketamine NS might be a better option for those struggling with TRD.
The study also looked at how much time was lost due to absenteeism, which is when someone misses work. Esketamine NS users had a smaller reduction in productivity loss due to absenteeism, but this difference was not statistically significant.
The results suggest that esketamine NS might be a more effective treatment for those with TRD. It could lead to better daily functioning and work productivity, which are crucial for overall well-being.
This study provides hope for those who have not found success with traditional treatments. However, it's important to note that everyone's experience with depression is unique. What works for one person might not work for another.
The study highlights the importance of finding the right treatment for each individual. It also shows that there are options available for those who have not found relief with standard treatments.
Actions
flag content